Aurobindo Pharma

Aurobindo Pharma is India's most US-exposed large-cap generics manufacturer and one of the most vertically integrated generic drug companies anywhere. Its value chain runs from fermentation-based key starting materials, including India's largest Penicillin-G plant at Kakinada, through APIs to finished dosages sold in more than 150 countries.

The company had 599 cumulative USFDA ANDA approvals as of October 2026, a figure that includes tentative approvals, and it is one of the largest suppliers of generic prescriptions in the US by volume. Its European formulations business crossed EUR 1 bn in revenue in FY26.

The investment debate centres on three things:

• whether Aurobindo can convert scale-driven volume leadership into a higher-margin mix of injectables, biosimilars and complex generics;

• whether it can expand onshore US manufacturing (Lannett, Raleigh, Dayton);

• whether it can contain repeated USFDA compliance issues at its Eugia sterile sites.

FY26 revenue was INR 33,653 Cr with a 20.4% EBITDA margin. That trails peers such as Sun Pharma, which earns about 30%. The gap reflects the company's commodity-heavy mix, and it is also the main source of potential upside if mix shift succeeds.

---

Company self-description

In its standard boilerplate on press releases (Q1 FY27 press release, 5 Aug 2026), Aurobindo describes itself as an integrated global pharmaceutical company headquartered in Hyderabad. It says it develops, manufactures and commercialises a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and APIs in more than 150 countries. It cites more than 30 manufacturing and packaging facilities approved by regulators including the USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa's regulator and Brazil's ANVISA.

Aggregators citing its annual report summarise the principal activity as manufacturing and marketing APIs, generic pharmaceuticals and related services.

Independent characterisation

Aurobindo is a scale generic manufacturer with four distinguishing features.

1. Vertical integration. The company is backward-integrated from fermentation: Pen-G, 6-APA and 7-ACA at Lyfius. It then moves through APIs at Apitoria and into finished dosages. In betalactam antibiotics, this gives it structural cost leadership and protection from Chinese supply disruption.

2. US volume leadership in oral solids. This is a low-price, high-volume franchise. The company is now augmenting it with onshore capacity:

   • Lannett in Seymour, Indiana, with roughly 4 bn doses of annual capacity;

   • Aurolife in Raleigh, North Carolina;

   • a newer facility in Dayton, New Jersey.

3. Diversification away from the US. Europe is now about a third of revenue, after a string of acquisitions between 2014 and 2019: Actavis Western Europe, Generis and Apotex Europe. Growth Markets and ARV tenders add further spread.

4. Optionality in specialty businesses. Eugia covers injectables, oncology, hormonals and peptides. CuraTeQ covers biosimilars, with filgrastim, pegfilgrastim, trastuzumab and bevacizumab approved in various markets and denosumab and omalizumab in late-stage development.

Revenue model

Almost all revenue is product revenue: sales of finished formulations and APIs. The disclosed mix is:

• formulations, 88.5% of Q1 FY27 revenue (INR 8,101 Cr of INR 9,150 Cr);

• API, 11.5%.

Value-chain position, customers and end-markets

Upstream: fermentation KSMs and intermediates (Lyfius), plus APIs (Apitoria, with multiple units at Parawada and elsewhere in Andhra Pradesh and Telangana).

Midstream: finished-dose manufacturing in India (APL Healthcare, Eugia), the US (Aurolife Raleigh, Dayton, Lannett Seymour), Europe (Portugal and others) and China (Luoxin Aurovitas JV, now 50%).

Downstream customers: - US wholesalers, group purchasing organisations and retail pharmacy chains;

• European tender payers and pharmacies;

• global health procurement bodies for ARVs (PEPFAR- and Global Fund-linked tenders);

• emerging-market distributors;

• Indian prescribers through Auropharm's branded generics.

End-markets: the US (41.2% of Q1 FY27 revenue), Europe (32.1%), Growth Markets (11.6%), ARV (3.6%) and API (11.5%), all per the Q1 FY27 press release.

Stated strategic themes (FY26 annual results and Q1 FY27 commentary)

Business-model resilience: The Vice Chairman and MD attributed FY26 to the resilience of the business model, an extensive portfolio, consistent volumes, operating efficiencies and disciplined execution (Q4 FY26 release). He described Q1 FY27 as "a strong note" built on disciplined execution, operational excellence and portfolio strength.

USD 2 bn US revenue aspiration: Management aims to reach USD 2 bn in US revenue in the near term, roughly within two years. The path includes the Lannett acquisition, in-licensing and new launches (Q4 FY26 call; ICICI Securities).

Europe margin expansion: Europe's EBITDA margin is just above 20%, and management expects improvement after the business crossed EUR 1 bn.

Specialty mix shift: This covers injectables (Eugia), biosimilars (CuraTeQ, at least 10 launches by 2030) and peptides.

Backward integration: The Pen-G plant is expected to make a meaningful EBITDA contribution from FY27 (ICICI Direct). A secondary report cites 50-100 bps of cost savings.

Corporate simplification: - India branded generics moved into Auropharm (Jul 2026);

• Eugia entity consolidation proposed;

• business-specific subsidiaries, which could later allow stake sales or value unlocking. This is speculative; independent directors have reportedly evaluated it in the past, per a secondary source.

Initiatives in the last 24 months (to Oct 2026)

Guidance

FY27 EBITDA margin above 21%: This target is reported by a secondary source from the May 2026 call.

US revenue of USD 2 bn: in the near term.

Europe: margin improvement.

Aurobindo's US portfolio alone spans several hundred approved molecules: 599 ANDA approvals as of 3 Oct 2026, including tentative approvals, from 896 ANDAs filed as of 30 Jun 2026. A literal product-by-product catalogue is not feasible. Below are the platform categories and the named products disclosed in 2025-2026 filings and press releases.

US Formulations: oral solids and other non-sterile dosage forms

US: controlled substances and onshore manufacturing (Lannett, from 30 Jun 2026)

Portfolio: Lannett is a complex generic manufacturer focused on non-opioid DEA-controlled substances, especially ADHD therapies, along with generic liquids (deal announcement, July 2025).

Scale: CY2024 revenue was USD 286 mn (MarketScreener deal summary).

Manufacturing: The Seymour, Indiana plant can scale to about 4 bn doses a year. It passed a USFDA inspection on 17-21 Aug 2026.

Divestitures: Four products, including an immunosuppressant and a stomach-acid reducer, were divested to Quagen Pharmaceuticals as the FTC condition for clearance.

CDMO: Lannett adds a growing contract development and manufacturing business.

Specialty injectables (Eugia Pharma Specialities)

Scope: Eugia makes sterile injectables, including oncology, hormonals, penems and peptides, along with ophthalmics.

Named product: USFDA approval for Dasatinib tablets came through Eugia (oral oncology from Eugia's oncology unit; disclosed in the company's 2025-26 event list).

Manufacturing units: - Unit-III (Pashamylaram, Telangana) makes terminally sterilised products. It is under a second OAI as of June 2026.

• Unit I (Telangana) makes aseptically processed injectables. It received a Warning Letter in August 2026 and contributes about 2% of group revenue.

• Unit II was also cited for similar aseptic deficiencies, according to the Warning Letter commentary.

• Eugia Steriles and Eugia SEZ are proposed to be merged into Eugia (secondary report; August 2026).

US launch timing: Pending approvals from Unit-III constrain new US injectable launches (ICICI Securities, May 2026).

Biosimilars (CuraTeQ Biologics)

CuraTeQ's stated ambition is to launch at least 10 biosimilars by 2030 (TipRanks, citing company announcement). Its Hyderabad drug-substance and drug-product facility is EU-GMP and WHO-GMP certified. Brazil's ANVISA granted GMP approval on 21 Jul 2026, after a 11-15 May 2026 inspection covering four biosimilar products.

Europe Formulations

The business is a multi-country generics, OTC and hospital portfolio built through acquisitions of Actavis Western Europe (2014), Generis (2017) and Apotex Europe (2019).

Growth Markets and India

International: Branded and unbranded generics in Brazil, South Africa, Canada, Indonesia and other emerging markets.

India: Branded generics now operate through Auropharm Limited (effective 1 Jul 2026), with domestic sales of INR 104 Cr in Q1 FY27.

Recent India acquisition: Khandelwal Laboratories, completed in FY26.

ARV

The company manufactures first- and second-line HIV antiretrovirals for global health procurement.

API (Apitoria, Lyfius)

Product range: Betalactam APIs (penicillins and cephalosporins), non-betalactam APIs, and fermentation intermediates.

Lyfius plant: Designed capacity includes 15,000 TPA Pen-G, 2,000 TPA 7-ACA and 4,200 TPA 6-APA, plus co-line products of 1,800 TPA each of amoxicillin trihydrate and ampicillin trihydrate (project feasibility data via PatSnap).

2026 USFDA inspections: - Apitoria Unit-VI, Parawada (Anakapalli): three procedural observations, Aug 2026.

• Apitoria Unit-IV: one observation, Sep 2026.

• Apitoria Unit-II: inspection completed, Sep 2026.

• Apitoria Unit-V: inspection classified (FY26).

Pricing model

Pricing follows standard generic economics: contract and tender pricing with US wholesaler and GPO consortia, European tenders and reference pricing, and global-health tenders for ARVs. Individual product pricing is not publicly disclosed.